Tag Archive for: CTX

Vivet Therapeutics to Present Key Findings on its Gene Therapy Program forCerebrotendinous Xanthomatosis at the American Association for the Study of Liver Diseases Annual Meeting

/in

Gene therapy program VTX-806 demonstrated normalization of toxic bile acid metabolites in blood, liver, tendons and brain in a CTX mouse model for the first time, holding promise for curative treatment Long term characterization of B6.129-Cyp27a1tmlEl t/J CTX mouse model showed measurable motor alterations similar to those described in CTX patients validating model for translation […]

Read more

European Commission Grants Orphan Drug Designation for Vivet Therapeutics Gene Therapy Product for the Treatment of Cerebrotendinous Xanthomatosis (CTX)

/in

Pre-clinical data of VTX-806 in mice demonstrated normalization of metabolic parameters in blood and brain, and of upregulated compensatory enzymes EUR 4.9 million funding provided by French Government to develop VTX-806 as an effective treatment option to stabilize or reverse symptoms in CTX patients Paris, France, September 5, 2024 – Vivet Therapeutics (“Vivet”), a clinical […]

Read more

Vivet Therapeutics to Participate and Present at Upcoming Scientific and Investor Conferences in April through to June 2024

/in

Paris, France, April 23, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited liver metabolic disorders, is pleased to announce that its management team will be participating and presenting at the following scientific and business conferences in April, May and June in 2024. Read more…

Read more

Vivet Therapeutics receives EUR 4.9 million to advance development of a gene therapy

/in

Vivet Therapeutics receives EUR 4.9 million to advance development of a gene therapy for the treatment of cerebrotendinous xanthomatosis  Funding from French Government as part of the France Health Innovation Plan 2030 operated by Bpifrance  Paris, France, February 1, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotech company developing novel and long-lasting gene therapies for […]

Read more